Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss

Twelve-month phase 3 data evaluating clascoterone 5% solution for male pattern hair loss provide encouraging evidence regarding the topical therapy’s long-term safety, tolerability, and efficacy, according to Joshua Zeichner, MD, associate professor of dermatology at Mount Sinai Hospital in New York City. In the next part of this Dermatology Times Expert Persectives video series, Zeichner explains the investigational treatment’s mechanism of action and potential role in the management of androgenetic alopecia.

Long-Term Safety and Sustained Efficacy

Across the 12-month treatment period, patients who received clascoterone 5% solution demonstrated a safety and tolerability profile similar to that of patients treated with vehicle. Importantly, no significant hormone-related adverse effects were observed during the study period. According to Zeichner, these findings are consistent with previous studies demonstrating minimal systemic absorption of the compound, an important consideration for a therapy designed to target androgen signaling.

Efficacy also continued with longer-term treatment. Patients who continuously used clascoterone 5% solution demonstrated a 2.39% increase from baseline in target-area hair density at 12 months, suggesting continued improvement with ongoing treatment.

Mechanism of Action and Current Formulations

The mechanism of clascoterone is particularly relevant to the pathophysiology of androgenetic alopecia. The topical androgen receptor inhibitor blocks the interaction between dihydrotestosterone (DHT) and androgen receptors within hair follicles. Because androgen signaling plays a central role in follicular miniaturization, disrupting this interaction may interfere with the signals that contribute to progressive hair follicle shrinkage and loss.

Clascoterone is already available as a 1% cream formulation for the treatment of acne. In that indication, the medication blocks androgen receptor activation in the sebaceous glands, reducing sebum production and inflammation. The formulation being investigated for male pattern hair loss is a higher-concentration 5% solution designed for topical application to the scalp.

A Potential Foundational Therapy

The potential advantage of clascoterone for androgenetic alopecia, Zeichner explained, lies in its ability to address the hormonal pathway involved in hair follicle miniaturization while being delivered topically. This approach could potentially provide targeted activity at the follicle while limiting systemic exposure and associated hormone-related adverse effects. Although further evaluation and regulatory review are needed, the 12-month findings highlight clascoterone 5% solution as a promising potential addition to the therapeutic landscape for male pattern hair loss.

“A drug like clascoterone 5% solution that blocks that interaction through a topical application in an effective way and a safe way without potential systemic hormone side effects means that this drug can be a foundational treatment for all patients with male pattern hair loss,” Zeichner concluded.